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ABSTRACT
Objective To assess which of three triage strategies for
womenwithborderlineabnormalcervicalsmearresultsin
the best psychosocial outcomes.
Design Pragmatic, non-blinded, multicentre, randomised
controlled trial.
Setting 18 family planning clinics across Australia,
covering both urban and rural areas, between January
2004 and October 2006.
Participants Women aged 16-70 years (n=314) who
attended routine cervical screening and received a
borderline cervical smear.
Interventions Patients were randomly assigned to human
papillomavirus (HPV) DNA testing (n=104), a repeat
smear test at six months (n=106), or the patient’s
informedchoiceofeithertestsupportedbyadecisionaid
(n=104). Psychosocial outcomes were assessed at
multiple time points over 12 months by postal
questionnaire.
Main outcome measures We assessed health related
quality of life (SF36 mental health subscale), cognitive
effects(suchasperceivedriskofcervicalcancer,intrusive
thoughts),affectiveoutcomes(generalanxiety[state-trait
anxiety inventory]), specific anxiety about an abnormal
smear (cervical screening questionnaire), and
behavioural outcomes (sexual health behaviour and
visits to the doctor) over 12 months of follow-up.
ResultsAt two weeks, some psychosocialoutcomes were
worse for women allocated to HPV testing compared with
those in the smear testing group (SF36 vitality subscale:
t=−1.63, df=131, P=0.10; intrusive thoughts χ
2=8.14,
df=1, P<0.01). Over 12 months, distress about the
abnormal smear was lowest in women allocated to HPV
testing and highest in the repeat smear testing group
(t=−2.89, df=135, P<0.01). Intrusive thoughts were
highest in patients allocated to HPV testing (25%,
compared with 13% in the informed choice group;
difference=12%, 95% CI −1.1% to 25.1%). Women in the
HPVDNAgroupandtheinformedchoicegroupweremore
satisfied with their care than women allocated to repeat
smear testing.
Conclusions Although the psychosocial effect was
initiallyworseforwomenallocatedtoHPVtriage,overthe
full year of follow-up this intervention was better for
women’s psychosocial health than repeat smear testing.
Offering informed choice could have a small advantage
forcognitiveoutcomes,butinviewoftheadditionaleffort
and logistical complexity that this intervention requires,
HPV testing alone can be justified for most women.
Trial Registration actr.org.au Identifier: 12605000111673
INTRODUCTION
Despitedevelopmentanduseofthehumanpapilloma-
virus (HPV) vaccine, cervical screening remains the
primary method for the prevention of cervical cancer.
Debatecontinuesaboutthebeststrategiesfortheman-
agement of cervical abnormalities detected by
screening.
12 HPV DNA testing is a new option for
the management of low grade and borderline cervical
abnormalities, also known as atypical cells of undeter-
mined significance (ASCUS) in the United States, or
non-specific minor changes/possible low grade squa-
mous intraepithelial lesions (LSIL) in Australia. This
category accounts for about 3-4% of all smear test
results, and affects over 100000 women in the United
Kingdom every year.
3 Unlike the conventional man-
agementforthisgroup(repeatcervicalscreeningat6to
12 months), HPV triage testing can immediately iden-
tify women at higher or lower risk of having a more
serious cervical abnormality who require colposcopic
follow-up. HPV triage involves an immediate HPV
DNA test with women whotest HPV positive (indicat-
ing the presence of oncogenic HPV viral types),
recommendedforcolposcopy.Since2001,HPVtriage
has been recommended in the US for women with
ASCUS, and its introduction within the cervical
screening programme of the UK National Health Ser-
vice is currently being implemented in sentinel sites
across England and Wales (NHS Cervical Screening
Programme HPV Sentinel Sites Implementation Pro-
ject www.cancerscreening.nhs.uk/cervical/hpv-senti
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ing programme is currently under consideration.
HPV triage testing has potential downsides. It could
result in an explicit diagnosis of a sexually transmitted
infection and an increased rate of referral to
colposcopy,
4 both of which are known to cause
anxiety.
5-8 Cross sectional and qualitative studies indi-
cate increased psychological burden among women
testing positive for HPV in triage and primary HPV
screening, at least in the short term.
578Whether these
potential psychological harms are offset by the faster
follow-up and reduced waiting times offered by HPV
triage testing is currently unknown.
The IMAP study (Improving Management of
AbnormalPapSmears)wasdesignedtoassessthe psy-
chosocial effect of HPV triage testing compared with
conventional management by repeat smear testing for
women with a borderline smear result over one year.
Additionally, the study assessed the effect of informed
choice on psychosocial wellbeing. Increasingly,
informed choice is recognised as important within
screening programmes.
9-11 This process acknowledges
thatpotentialparticipantshavetherighttobeinformed
of the benefits and harms of screening, and can there-
fore make their own informed decision about their
management. The effect of informed choice in studies
ofscreeningandtreatmentsuggeststhatthereareshort
term benefits, but the evidence of long term outcomes
for health and quality of life remains uncertain.
12 The
effects of informed choice beyond the initial period of
decision making need to be ascertained.
13
This study therefore set out to assess the effect of
management by HPV triage or a repeat smear test,
and the effect of informed choice of management
(HPV triage or repeat smear testing) supported by a
decision aid, compared with clinician directed man-
agement on psychosocial outcomes over a year for
women with a borderline smear.
The study was done in Australia, which has had a
national cervical screening programme in operation
since 1991. Psychosocial outcomes included quality
of life measures as well as measures of cognitive, emo-
tional, and behavioural wellbeing.
METHODS
Participants
Inall,314womenaged16to70yearswhowereattend-
ingroutinecervicalscreeningatfamilyplanningclinics
across Australia were identified. All women had
received a smear test result categorised as non-specific
minor changes with or without HPV effect (koilocyto-
sis). This category represented the closest Australian
equivalent to the categories used in the UK and US of
borderline and atypical cells of undetermined signifi-
cance (ASCUS), and will be referred to using the UK
terminology, borderline smear. Only women with an
index borderline abnormality were included (that is,
this was their first cervical abnormality detected, with
no history of external visible genital warts within the
past two years). Women who were pregnant or who
became pregnant during the course of the study and
thosewhowereunabletocompleteawrittenquestion-
naire in English were excluded.
Recruitment
Participants were recruited from 18 clinics across Aus-
tralia,coveringurbanandruralareas,betweenJanuary
2004andOctober2006.Eligiblewomenwhomatched
the selection criteria were identified by a research
nurseat eachclinicand senta studyinformation book-
let, an invitation letter, and consent form, along with
the results of their smear test. Women then received a
follow-up telephone call from a family planning
researchnurse. Womenwilling to participate returned
their consent form to researchers at the University of
Sydney and were recruited into the study.
Design
Participantswererandomisedcentrallybytheresearch
team within each clinic in blocks of three. Randomisa-
tion was not blinded, but was concealed from clinic
staff until allocation. Women allocated to the HPV
triage group were asked to arrange an appointment
for HPV testing at theirlocal clinicas soon as possible.
Women randomised to repeat smear testing were
asked to schedule an appointment in six months.
Women in the informed consent group were sent the
decision aid describing the advantages and disadvan-
tages of each management strategy (as described in
McCaffery et al).
14 They were then asked to choose
their preferred test by completing a preference form
and were advised to schedule a test appointment at
their local clinic.
The decision aid was developed using the Ottawa
framework.
15 Outcomes of management were based
on estimates from the Australian cervical screening
programme and from the ASCUS-LSIL triage study
(ALTS).
16-18 Women were given information about
each of the options and the characteristics of testing
with respect to the timing of follow-up and the likeli-
hood of referral to colposcopy (expressed as a natural
frequency out of a denominator of 100 women). Infor-
mation about the possible negative effect on quality of
life for each treatment strategy was described qualita-
tively. For HPV triage this outcome was given as the
possible diagnosis of an HPV infection, and for smear
testing was described as the six month waiting period
for a repeat test, which can cause anxiety in some
women (see web appendix 1). Previous analysis of the
decision aid indicated that womenrated it highly (82%
indicateditwasbalanced,99%reported“everythingor
most things” were clear, 85% indicated it was “about
therightlength”,and86%foundit“veryorsomewhat”
helpful
14 (www.psych.usyd.edu.au/cemped/communi
cation.shtml).
Clinical management
All index smears were done using conventional testing
methods.WomenreceivingHPVtestingwererequired
toattendtheirclinicforaswabusingtheDigeneHybrid
Capture 2 HPV DNA test (Gaithersburg, MD, USA).
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follow-up(ALTS2001).Womenwhotestedpositivefor
HPV were referred for colposcopy with a local public
provider.Thosewhotestednegativewererecalledfora
s m e a rt e s ta t1 2m o n t h s .
Womenallocatedtoorwhochosearepeatsmeartest
were advised to re-attend at six months. Participants
were subsequently managed according to the Austra-
lian guidelinescurrentat the timeof the study.
19At the
six month smear, women with a normal or borderline
result were recalled for a further repeat smear test six
monthslater. Those with moderate dyskaryosis (cervi-
cal intraepithelial neoplasia grade 2 [CIN2]) or above
were referred for colposcopy and women with mild
dyskaryosis (CIN1) could choose either colposcopy
or a repeat smear test.
Measures
Immediately after consent, participants were sent the
first study questionnaire to assess their demographic,
health, and psychological status. This questionnaire
aimed to be as close as possible to the receipt of the
index (first) abnormal test result. Psychosocial well-
being was then assessed at regular time points over
12 months after triage testing (figure 1). Post-triage
questionnaires were sent at two weeks and at three,
six, and 12 months. Participants allocated to or who
chose repeat smear testing received two additional
questionnaires before their six month smear test.
These additional questionnaires assessed waiting time
anxiety at two and four months, and were scheduled
around the same time as the two week and three
monthsquestionnairesintheHPVgroup.Forallques-
tionnaires a reminder letter and second copy of the
questionnaire was sent to non-responders after two
weeks. Women who failed to respond to the study
questionnaires or did not attend their test were sent a
non-attenders questionnaire (at three months after the
last date of contact) to identify the reason.
The studymeasureswere selected toreflectthe mul-
tifaceted psychosocial consequences of an abnormal
smear, with cognitive, emotional, and behavioural
outcomes
20 represented as secondary outcomes. The
mental health component of the SF36
21 was used to
provide a generic measure of quality of life and was
seen as the primary outcome (figure 2). Demographic
variablesmeasuredatthetimeofthefirstquestionnaire
included age, education, employment, marital and
relationshipstatus,children,andethnicity.Healthvari-
ables included smoking behaviour, oral contraceptive
use, previous abnormal smear result, previous colpo-
scopy, and number of sexual partners.
The cognitive measures assessed included per-
ceived risk of cervical cancer,
22 perceived seriousness
ofcervicalcancer,worryaboutcervicalcancer,
23intru-
sive thoughts about the abnormal smear results (mea-
suredusingoneitemfromtheimpactofeventsscale),
24
satisfaction with health care in general, and women’s
satisfaction with the care received for their abnormal
cervical smear.
25
For emotional measures, we assessed anxiety using
the six item abbreviated state trait anxiety inventory
(STAI),
26 and measured distress and concern specific
to the abnormal smear using the cervical screening
questionnaire
23 and the psychosocial effects of abnor-
malPapsmearsquestionnaire(infectivityandrelation-
ships subscales).
27 We also assessed self esteem.
28
Behavioural measures included effect on sexual
behaviour (sexual health)
29 and help seeking beha-
viours, visits to a general practitioner (GP), and tele-
phone calls to the family planning clinic for
information and advice.
We assessed knowledge in the two week post-triage
questionnaire to investigate the effect of the decision
aid on the patients’ understanding of their manage-
ment options and their abnormal smear. The knowl-
edge scale included 10 items, with four relating to
understanding of key features of HPV (such as its link
with cervical abnormalities and cancer, high risk and
low risk HPV types, HPV latency, and prevalence).
The remaining six items related to understanding of
the abnormal cervical smear result, triage by smear
testing, and colposcopy follow-up. The response cate-
gorieswere“true”,“false”,and“notsure”,withcorrect
answers scored as 1 and incorrect or unsure responses
scored as 0.
Statistical methods
The analyses were done on an intention to treat basis.
We compared psychosocial outcomes across the three
trial arms cross sectionally at two weeks after the triage
test,andthenlongitudinallyforninemonths(fromthree
months to 12 months after the index result) using an
analysis based on area under the curve. There was loss
tofollow-up,withincreasinglossasthelengthoffollow-
up management increased (see figure 3). Three partici-
pantschangedtreatmentgroup.Twowithdrewfromthe
study after triage testing, and one did not complete any
follow-up questionnaires after the first psychosocial
questionnaire. These women were included in the sen-
sitivity analysis according to the arm they were origin-
ally randomised to.
Women with a borderline abnormal cervical smear (16-70 years) (n=314)
Randomisation
Psychosocial questionnaires at 2 weeks, 3, 6, 12 months after triage test 
HPV test
6 month repeat
smear test
6 month repeat
smear test
Human papillomavirus
(HPV) test
Decision aid plus informed
choice (HPV test or smear test)
Repeat smear
test at 6 months
First psychosocial questionnaire
Waiting time psychosocial questionnaire
1 and 2 (2 months and 4 months)
Fig 1 | Randomised trial design and psychosocial assessment
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To compare the scores two weeks after initial screen-
ing, a globalANOVAF-testwasused,allowing forthe
unbalanced design, to assess if any of the means were
different between groups. Only variables where the
ANOVA was statistically significant (at P<0.1) had
the pairwise analysis done, using t tests with a signifi-
cance level of P<0.05 and with
30 adjustment for
unequal variances. Differences significant at the 0.10
level have been reported. Non-parametric tests (Krus-
kal-WallisandWilcoxon)weredonetoensurethatthe
resultswererobusttonon-normalityanddifferencesin
variances between the groups. For the ordinal out-
comes with less than five categories, χ
2 tests for the dif-
ference in proportions were used for the global test
with pairwise comparisons if P<0.1.
Longitudinal analysis
ThedesignofthestudycomparingHPVtesting,which
happened soon after the index abnormal smear result,
with the six month follow-up smear test had a highly
unbalanced pre-triage waiting time. The effect of the
differentwaitingperiodswasexpectedtobeakeycom-
ponent of potential psychosocial difference and would
not be captured in the two week follow-up cross sec-
tionalcomparison.Similarly,acrosssectionalcompar-
ison at 12 months post-triage was not appropriate,
since for the HPV group this represents
12-13 months from the index abnormal smear and
for the repeat testing group represents around
18 months. We would therefore expect patients in the
repeat smeartesting group to have better psychosocial
outcomes. To assess the effect of the different waiting
periods, as well as the time period after the triage test,
an area under the curve analysis was used to obtain an
average per day for all the psychosocial outcomes (see
web appendix 2). The area under the curve method
allows for variation in follow-up schedules for the dif-
ferent study groups and also variation in the times at
whichwomencompletedquestionnaires.Theareawas
calculated between 90 and 365 days from the index
result using linear interpolation and linear extra-
polationifrequired(webappendix2).Thistimeperiod
was chosen to enable comparison between the groups
at 12 months of follow-up from the index abnormal
result, and to minimise the need for extrapolation of
questionnairedata.Onlyparticipantswithinformation
atthethree,six,or12monthspost-triagequestionnaire
and with at least two measurements on the outcome of
interest were included in the area analysis. For exam-
ple, for the measure for cervical screening specific dis-
tress, the area under the curve analysis was based on
four or more measurements for 175 women, three
measurements for 21 women, and two measurements
in only 13 women, a total of 209 women. This method
was used to minimise extrapolation of data from early
time points where psychological scores were worst.
The area under the curve was then divided by the
275 days (365−90 days) of follow-up to represent the
average of the psychosocial outcomes per day.
To comparemeanscoresacrossthe groups,we used
thesamemethodsdescribedforthecrosssectionalana-
lysis,withaglobalANOVAFtestfollowedbypairwise
comparisons using t tests and χ
2 statistic for categorical
outcomes. Effect size for the SF36 mental health com-
ponent subscales
3132 were calculated using both the
sample standard deviation and Australian population
standard deviation.
33 Findings were similar using
either method, so the effect sizes using Australian
population data are reported.
Sensitivity analysis
Theareawasdividedintothreetimeintervals.Period1
(days90-160)indicatedthetimeatwhichmostwomen
(over 90%) receiving the HPV screening were tested.
Period 2 (days 161-320) represented the time at which
over 90% of women allocated to or choosing repeat
cervical smear received their test. Period 3 (days 321-
365) represented the period at which most women in
both arms had completed testing. The period scores
were then plotted across time by study group to assess
whether effects varied by time, particularly for the last
period where extrapolation was more likely.
Around two thirds of the sample were included in
the area analysis. To assess the robustness to the inclu-
sion and exclusion criteria, sensitivity analysis was
done first, including all participants who had at least
two data points but did not have an appropriate end
point(follow-upatthree,six,or12monthsaftertesting,
259 women, 82% of the total sample). All participants
withonlyonedatapointwerethenincludedintheana-
lysis by assuming that their observed value remained
constant with time (304 women, 97% of the total sam-
ple). The results of the sensitivity analysis showed no
material differences to the interpretation of the study
findings.
Sample size
We aimed to recruit 120 participants per randomised
arm, to retain 100 per group after allowing for some
loss to follow-up. This sample size was sufficient to
detect differences in proportions between trial arms
of 5% versus 18%; 10% versus 26%; 20% versus 39%
at the 0.05 significance level with 80% power. The
power calculation was based on differences in binary
outcomes (proportions), with the assumption that for
continuous outcomes, we would have more power to
detect differences.
All the analyses were done using SAS version 9.1.
Test
Quality of life–eg, SF36
Behavioural
effects
eg, GP visits
Emotional
effects
eg, anxiety
Cognitive effects
eg, perceived
risk
Fig 2 | Framework for understanding and assessing
psychosocial effects.
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ThetrialtookplacebetweenJanuary2004andAugust
2007. 330 women were enrolled in the study, with 16
women excluded as not meeting the eligibility criteria.
Threehundredandfourteenwomenwererandomised
to the three trial arms. In total, 261 (83%) participants
completed at least two psychological questionnaires
and 235 (75%) participants met the criteria for inclu-
sion in the analysis.
Table 1 shows the demographic and health charac-
teristicsofthesampleincludedintheanalysis.Charac-
teristics were similar across each of the groups, with
some small imbalances in variables relating to smear
test result,previous experienceof an abnormality,and
relationship and sexual history (index test result, pre-
vious abnormal smear test, previous colposcopy, cur-
rent relationship status, and number of sexual
partners). The potential confounding by these vari-
ables was assessed in all subsequent analyses. Includ-
ingtheminthemodelsdidnotaffecttheinterpretation
oftheresults,thereforewechosetopresentthesimpler
models.
In the informed choice group, 61 (64%) women
chose HPV triage and 35 (36%) chose repeat smear
testing.
14 Of the 151 women who received the HPV
test, 57 (38%) tested positive and 94 (62%) tested nega-
tive.
The distribution of the psychosocial measures
assessed in the two week questionnaire are described
intable 2withcomparativedatagivenfromotherrele-
vantsamples whereavailable.The SF36mental health
component scores were lower (worse) than those
reported in a study of Australian women with a minor
medical condition (such as allergies, back problems,
arthritis,rheumatism,orbronchitis)buthigher(better)
than women with a serious medical condition (includ-
ing heart conditions, stroke, and cancer).
34
Theimpactofeachcategoryofthepsychosocialout-
comes at two weeks and over one year is described
below and presented in tables 3 and 4.
Effect on health related quality of life
At two weeks after triage, health related quality of life
was worse in the HPV testing group. There was weak
evidence of an effect on the SF36 vitality subscale
(F=2.46, df=2,196, P=0.09) for women in the HPV
group compared with the cervical smear group (t=
−1.63, df=131, P=0.1; effect size=0.33) and compared
with the informed choice group (t=−2.00, df=141,
P=0.05, effect size 0.27). Over a year, there were con-
sistently higher scores on all the SF36 subscales in the
Patients assessed for eligibility (n=1116)*
Enrolment (n=330)
Randomised (n=314)
Excluded (n=16):
  Did not meet inclusion criteria (n=9)
  Other reasons (n=7)
Analysed (n=99) 
Included in main analysis (n=87)
Included in sensitivity analysis (n=99)†
Exclusions from main analysis who
  completed less than 2 follow-up
  questionnaires (n=8)‡:
    Completed 2 or more questionnaires but
      did not meet inclusion criteria (n=8)‡
    Completed 0 or 1 questionnaire (n=0)
Analysed (n=102) 
Included in main analysis (n=77)
Included in sensitivity analysis (n=102)†
Exclusions from main analysis who
  completed less than 2 follow-up
  questionnaires (n=20)‡:
    Completed 2 or more questionnaires but
      did not meet inclusion criteria (n=5)‡
    Completed 0 or 1 questionnaire (n=15)
Analysed (n=104) 
Included in main analysis (n=71)
Included in sensitivity analysis (n=104)†
Exclusions from main analysis who
  completed less than 2 follow-up
  questionnaires (n=31)‡:
    Completed 2 or more questionnaires but
      did not meet inclusion criteria (n=19)‡
    Completed 0 or 1 questionnaire (n=12)
Allocated to HPV (n=104):
  Received allocated intervention, HPV test
    (n=92)
  Did not have an HPV test (n=12)
Allocated to informed choice (n=104):
  Received allocated intervention, HPV or
    smear test (n=82)
  Did not receive HPV or smear test (n=22)
Allocated to repeat cervical smear (n=106):
  Received allocated intervention of repeat
    testing at 6 months (n=72)
  Did not receive a repeat test (n=34)
Withdrawn (n=9):
  Became pregnant (n=3)
  Miscellaneous (moved, went overseas
    etc) (n=6)
Follow-up
Analysis
Allocation
Withdrawn (n=7):
  Became pregnant (n=1)
  Miscellaneous (moved, went overseas
    etc) (n=6)
Withdrawn (n=4):
  Became pregnant (n=2)
  Miscellaneous (moved, went overseas
    etc) (n=2)
*Women assessed for eligibility included those who were potentially ineligible for the study but who could not be identified in advance for reasons such as this
  was not their index (first) borderline smear test result; or abnormal result (including genital warts) in the past 2 years; they were pregnant or intending to get
  pregnant within the next 12 months; or were intending to travel over the next year. 
†Participants’ data were included in the study up to the point of their withdrawal. 
‡Inclusion criteria for analysis were if participant completed the two- week post-test questionnaire or completed a minimum of two of the following
  questionnaires: at 3, 6, or 12 months.
Fig 3 | Patient recruitment and retention
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however, these were not significant. Health related
quality of life scores generally improved in all the sub-
scales over the year in all trial groups.
At two weeks after testing, women in the HPV arm
reportedpooreroutcomesonthecognitivemeasureof
intrusive thoughts (57% (44 of 77) v 43% (28 of 65) in
the informed choice group and 32% (18 of 56) in the
smear test group ). Women in the HPV arm had more
intrusivethoughtsthantheothergroups(HPVvsmear
test: χ
2=8.14, df=1, P<0.01; HPV v informed choice:
χ
2=2.79, df=1, P=0.09). Over the year, the intrusive
thoughts were highest in the HPV group (25% (19 of
75)) and were lowest in the informed choice group
(13%; table 4) with a 12% difference between the two
arms(95%CI−1.1%to25.1%).Worriesaboutcervical
cancer were similar between the trial arms at 2 weeks,
but over the year showed greater variation, with the
lowest levels of worry, in the informed choice group
(8% (5 of 59) v 16% (12 of 74) in the HPV group and
15% (6 of 41) in the smear test group). Again these dif-
ferences were not significant (8% difference HPV v
informed choice, 95% CI −3.3 to 18.7; 7% difference
informedchoicevsmeartest,95%CI−19.1%to6.8%).
By contrast, women’s satisfaction with their targeted
care for their cervical abnormality was higher in the
HPV triage and informed choice groups than in the
cervical smear group at two weeks (HPV and smear
test: t=1.96, df=129, P=0.05; HPV and informed
choice: t=2.37, df=118, P=0.02). These scores
remained significantly different over the year for satis-
factionwith healthcare in general(fig 4 ; HPV v smear
test: t=2.70, df=136, P=0.01; informed choice v smear
test: t=2.11, df=135, P=0.04) and satisfaction with the
care received for the abnormal smear (HPV v smear
test: t=2.85, df=138, P=0.01).
For the emotional outcomes, there were no signifi-
cant differences between the groups at 2 weeks after
testing, although the HPV arm had slightly worse
scores across many of the measures. Over the year,
there was an improvement in emotional outcomes in
all groups. However, the HPV arm had lowest scores
onthecervicalscreeningspecificdistressmeasure(that
is, were least distressed) over the course of the year
(fig 5). There was evidence of a difference in specific
distressscoresovertheyearoffollow-up(F=4.35,df=2,
206, P=0.01), and in the pairwise comparisons the dis-
tress scores were significantly lower in the HPV arm
than in the smear testing arm (16.6 v 18.4, t=−2.89,
df=135, P<0.01).
Of the behavioural measures, there were few differ-
ences between groups on the sexual health scale or in
GP visits or calls to family planning clinics over the
course of follow-up. There was a small increase in the
number of GP visits in the HPV arm at two weeks;
however, this finding appears to be driven by a few
women in the HPV arm having a high number of GP
visits compared with those in the informed choice
group. The lower quartile, median, and upper quartile
number of GP visits was the same across all three
groups—0, 0, and 1, respectively—suggesting that for
most women, the number of GP visits at two weeks is
the same across the study.
Wecomparedwomen’sknowledgeandunderstand-
ing of HPV and smear testing between the informed
choice group and the allocated treatment groups.
Women in the informed choice arm had higher total
knowledge scores than women in either of the other
groups,whichindicatesthatthedecisionaidwasuseful
(mean score for informed choice 8.1 v HPV 7.3 and
cervical smear 7.2 out of 10, F=4.97, df=2, 160
P<0.01). We examined knowledge items relating to
HPV triage and smear testing separately to examine
whether this affected the results (table 5). Women in
the informed choice group had higher scores on the
smeartestingitemsthanintheothergroups.However,
their knowledge scores on the HPV testing items were
not significantlyhigher than womenin the HPV triage
arm, indicating that women allocated to HPV triage
had also become reasonably well informed about
their test.
DISCUSSION
Our findings suggest that although psychosocial out-
comes for women receiving HPV triage are worse in
the short term, over 12 months the outcomes seem to
be better than those seen with conventional manage-
ment by repeat smear testing. Two weeks after triage
testing, psychosocial outcomes were poorer for
women who received HPV testing than for those in
the repeat smear testing or informed choice groups,
with lower health related quality of life scores on the
SF36 vitality subscale, and with a small effect size of
0.27 (small <0.3). Women allocated to HPV testing
also had more intrusive thoughts about the abnormal
resultthantheothergroups.However,whenoutcomes
wereassessedoverafullyear,thepsychosocialburden
was worse for those participants who waited six
months for a repeat smear. The HPV and informed
choice groups had better psychosocial outcomes than
the repeat smear group, with a significant effect on the
specific distress measure for the HPV testing group
compared with the smear group. Both the HPV and
informed choice groups also rated satisfaction with
management consistently higher than did women in
the smear testing group.
Our findings suggest that HPV triage has an initial
negative effect on psychosocial wellbeing but that this
effectisquicklyresolved.Bycontrast,thepsychosocial
burden of triage by repeat smear testing remained
higherfor longerand resultedin a greatertotal burden
on the specific measure of distress for cervical screen-
ing. In a cross sectional study,Maissi et al
535indicated
that shortterm effectsof management(assessedat four
weeks after triage) were worse for women receiving
HPVtestingthanforthosewhowerenottested(receiv-
ing a repeat smeartest only). At six months,this differ-
ence had disappeared. Maissi found a higher level of
concernaboutsexualhealthintheHPVpositivegroup
at six months, but concerns about the test result itself
werehighestinthegroupwithanabnormalsmearwho
were not tested for HPV. However, these findings are
RESEARCH
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showed,usingarandomisedtrialmethodandcompar-
ing psychosocial outcomes for a year, that HPV triage
actually caused less screening specific distress overall
and resulted in greater satisfaction with management
than repeat testing. This finding highlights the impor-
tanceoflongtermfollow-upofpsychosocialoutcomes.
Multiple outcomes were included in this study in
order to comprehensively assess the various psychoso-
cial effects of management. Examination of multiple
independent outcomes can lead to spurious significant
findings, and increase type I errors. However, P value
adjustment when items are correlated, as the psychoso-
cial variables were in this study, is likely to be overly
Table 1 |Sociodemographic and health characteristics
HPV Informed choice Cervical smear Total
n% n% n% n
Age (years)
30+ 56 65.1 47 61.0 50 71.4 153
< 3 0 3 03 4 . 9 3 03 9 . 0 2 02 8 . 6 8 0
Education
Secondary education 35 42.2 18 24.3 25 35.7 78
Tertiary education 17 20.5 20 27.0 17 24.3 54
University 31 37.3 36 48.6 28 40.0 95
Employment
Full time 35 42.2 38 50.7 34 48.6 107
Other 48 57.8 37 49.3 36 51.4 121
Marital status
Married/ de facto 43 51.8 41 54.7 32 45.1 116
Single/divorced/ separated/ widowed 40 48.2 34 45.3 39 54.9 113
Children
Yes 51 60.7 35 46.7 34 47.9 120
No 33 39.3 40 53.3 37 52.1 110
Born in Australia
Yes 66 78.6 63 84.0 57 80.3 186
No 18 21.4 12 16.0 14 19.7 44
Non-English speaking background
Yes 13 15.7 7 9.3 7 9.9 27
No 70 84.3 67 89.3 59 83.1 196
Index smear test
HPV effect 12 13.8 7 9.2 12 16.9 31
No HPV effect 75 86.2 69 90.8 59 83.1 203
Contraceptive pill
Y e s 2 53 0 . 1 3 14 1 . 9 2 83 9 . 4 8 4
No 58 69.9 43 58.1 43 60.6 144
Number of sexual partners
1 1 61 9 . 0 1 11 4 . 7 1 01 4 . 1 3 7
2 to 5 29 34.5 25 33.3 22 31.0 76
6+ 39 46.4 39 52.0 39 54.9 117
Relationship status
In current
relationship
62 73.8 64 85.3 55 78.6 181
No current
relationship
22 26.2 11 14.7 15 21.4 48
Previous abnormal smear test
Y e s 3 64 3 . 4 2 02 6 . 7 2 33 2 . 9 7 9
No 47 56.6 55 73.3 47 67.1 149
Previous colposcopy
Y e s 1 51 7 . 2 1 21 5 . 6 1 62 2 . 5 4 3
No 38 43.7 25 32.5 25 35.2 88
No response 34 39.1 40 51.9 30 42.3 104
Smoking status
Y e s 2 02 3 . 8 1 92 5 . 7 1 72 3 . 9 5 6
No 64 76.2 55 74.3 54 76.1 173
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resulting in a loss of power to detect true effects. Hence,
we did not adjust for multiple outcomes in the current
study.
36 We highlight that the cognitive and emotional
itemsthatshowsignificantdifferencesbetweengroupsin
the one year analysis were highly specific to the experi-
ence andconcernsofanabnormalcervicalsmearresult,
as assessed by the cervical screening questionnaire mea-
sure(whichincludesconcernsaboutfertility,gynaecolo-
gical health, and cervical cancer), and the intrusive
thoughtsmeasure,whichassessedfrequencyofthoughts
women had about their abnormal smear results.
ArandomisedtrialbyKitcheneretal
37examinedthe
psychological effect of primary HPV testing. The
authors compared short term psychological and psy-
chosexual outcomes at two weeks between women
who were either given or not given their HPV test
results. There were almost no differences in outcomes
between the two groups. The findings indicated a net
neutral effect of HPV testing in the short term; how-
ever, there are currently no long term data available
for the outcomes from this trial.
Ourresultssuggestthattheeffectofinformedchoice
of management supported by a decision aid is uncer-
tain. At two weeks after testing, the informed choice
group had significantly better psychosocial outcomes
than the HPV testing group, as measured by the SF36
vitality subscale, with a moderate effect size (0.33).
Table 2 |Distribution of psychosocial measures in the two week questionnaire
n
Possi-
ble
range Min
Med-
ian IQR Max
Mean
(SD)
Relevant comparison scores where
available
SF36: mental health combined score Combined mental health subscales
score
196 0-100 11.5 48.9 38.6-
54.5
65.4 45.8
(11.5)
PopulationnormsforAustralianwomen
aged 25-64 years range from 48.3 to
50.6. (ABS 1995)
SF36: vitality Feelingenergeticand fulloflifeversus
tired and worn out
199 0-100 0 55 40-65 100 52.4
(18.7)
*Medical conditions: none=73.54;
minor=65.74; serious=54.98;
depression=62.35
SF36: social functioning Extentphysicaloremotionalproblems
interferingwithnormalsocialactivities
199 0-100 12.5 100 75-100 100 81.9
(22.8)
Medical conditions: none=95.76;
minor=90.5; serious=78.87;
depression=90.07
SF36: role emotional Extent emotional problems interfere
with work or daily activities
196 0-100 0 100 66.7-
100
100 77.2
(35.6)
Medical conditions: none=96.34;
minor=88.26; serious=74.85;
depression=87.86
SF36: mental health General mental health including
depression and anxiety
199 0-100 20 72 60-84 100 70.3
(16.3)
Medical conditions: none=85.72;
minor=83.61; serious=68.97;
depression=83.78
Perceived severity† Perceived severity of an abnormal
smear
192 0-10 0 5 3-7 10 4.9
(2.2)
–
Perceived risk of cervical cancer† Perceived risk of cervical cancer
compared with others
198 1-7 1 4 2-5 7 3.7
(1.6)
–
Intrusive thoughts† ThoughtaboutabnormalsmearwhenI
didn’t want to
198 1-4 1 2 2-3 4 2.3
(0.9)
–
Worry† Worry about getting cervical cancer 196 1-4 1 2 2-2 4 2.1
(0.8)
–
Satisfaction generally Satisfaction with healthcare generally 197 4-20 4 15 13-16 20 14.6
(2.9)
–
Satisfaction with care Satisfactionwithcarefortheabnormal
smear
196 0-10 0 9 8-10 10 8.3
(1.9)
–
Anxiety (STAI) † State of anxiety (eg, calm, tense,
relaxed)
187 20-80 20 36 23.3-
36.3
80 36.3
(13)
Population norm for women is 35.
Scores more than 49 seen in women
with anxiety disorder
Cervical screening questionnaire † Distress relating to abnormal smear,
including worries about fertility,
cancer, gynaecological health
190 0-36 6 18 15-21 29 18.3
(4.7)
Smear result normal=8.9; smear result
abnormal or unsatisfactory and HPV
positive=17‡
PEAPS Q: infectivity† Worry about infectivity of abnormal
smear to sexual partners
179 2-10 2 2 2-4 10 3
(1.8)
–
PEAPS Q: relationships† Worry about effect on sexual
relationships of abnormal smear
180 3-15 3 3 3-5 15 4.5
(2.5)
–
Relationship concerns Worries about current, previous, and
future sexual partners
151 3-15 3 9 9-9 13.5 9.2
(1.5)
–
Self esteem General self esteem 196 10-40 13.3 30 29-34 40 30.9
(4.5)
–
Sexual health Interestinsex,frequencyandnegative
feelings about sex
174 3-15 3 9 7.5-9 15 8.5
(2.1)
–
IQR=interquartile range, STAI=state-trait anxiety inventory, PEAPS Q=psychosocial effects of abnormal Pap smears questionnaire.
*Mean scores for comparison groups differing in medical and psychiatric conditions, no medical conditions, minor medical conditions, serious medical conditions, depression.
34
†Higher scores indicate poorer psychological outcomes. For all other measures, higher scores indicate better psychological outcomes.
‡We included an additional response category into this scale since it has previously been criticised for having unbalanced response categories.
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werebetteronmanyofthepsychosocialmeasuresover
12 months compared to the other trial arms, scores
were not significantly different, and effect sizes all fell
within the small range (<0.3). The cognitive measure,
intrusive thoughts, showed a notable difference com-
pared with HPV testing (12%) over 12 months.
Althoughnotsignificant,theconfidenceintervalsindi-
cate that informed choice could offer an advantage to
this outcome over HPV testing. Worry about cervical
cancer demonstrated a similar although weaker pat-
tern.
We conclude that offering women an informed
choice offers uncertain benefit compared with HPV
triage over 12 months, with the caveat that there
might potentially be an advantage of informed choice
on the cognitive outcomes, intrusive thoughts, and
worry. Informed choice is also likely to be better than
allocating women directly to repeat smear testing,
which had the worst psychosocial outcomes. Women
in the informed choice group had significantly higher
overallknowledgescoresthantheothergroups,which
mightbeanimportantbenefit.However,inviewofthe
extraeffortandcostthatinformedchoicerequireswith
respecttoprovidingalternativeservices,itmayormay
not be seen as worthwhile for these outcomes.
Importantly, the knowledge measure also indicated
that women in the HPV arm became well informed
about HPV triage and the important characteristics of
HPV and its association with cervical cancer. All
women testing HPV positive in the study were pro-
vided with a high quality information leaflet (see web
appendix 3) provided by the New South Wales Cervi-
calScreeningProgram.Thisfactormighthavereduced
some of the anxiety in the HPV group. Previous
research has found anxiety and distress about the
HPV test result is associated with poor understanding
and confusion about HPV infection, and that poor
understanding is often widespread among women
undergoing HPV testing.
53839
We know of only one previous study offering
women choice in management of borderline cervical
abnormalities. This study offered women the choice
between a repeat smear test or immediate colposcopy,
Table 3 |Psychosocial outcomes at two weeks after triage
Trial arm mean scores
Overall P value
P value for pairwise comparisons*
HPV IC RS HPV v RS HPV v IC RS v IC
Quality of life
SF36: mental health
combined score
44.3 47.0 46.3 0.35 –– –
Vitality 48.7 55.2 54.1 0.09 0.10 0.05 –
Social function 79.4 84.7 82.1 0.39 –– –
Role emotional 74.3 80.3 77.4 0.61 –– –
Mental health 68.5 71.3 71.6 0.46 –– –
Cognitive
Perceived severity† 4.9 5.0 4.8 0.91 –– –
Perceived risk† 3.5 3.9 3.8 0.24 –– –
Intrusive thoughts†‡ 57% 43% 32% 0.02 <0.01 0.09 –
Worry†‡ 25% 23% 24% 0.98 –– –
Satisfaction generally 14.5 15.1 14.2 0.22 –– –
Satisfaction with care 8.5 8.6 7.8 0.04 0.06 – 0.02
Emotional
Anxiety (STAI)† 11.5 10.5 10.6 0.25 –– –
Distress (CSQ)† 18.7 17.9 18.2 0.62 –– –
PEAPS-Q: infectivity† 3.1 3.0 2.9 0.68 –– –
PEAPS-Q:
relationships†
4.7 4.5 4.3 0.74 –– –
Relationship concern 9.2 9.4 9.0 0.39 –– –
Self esteem 30.5 31.2 31.2 0.53 –– –
Behavioural
Sexual health 8.5 8.7 8.5 0.88 –– –
Visits to GP/doctor§ 0( 1 ) 0( 1 ) 0( 1 ) 0 . 0 8 – 0.02 –
Calls to family
planning clinic§
0( 1 ) 0( 0 ) 0( 0 . 5 ) 0 . 5 5 –– –
RS=repeat smear, IC=informed choice, STAI=state-trait anxiety inventory, CSQ=cervical screening questionnaire, PEAPS-Q=psychosocial effects of
abnormal Pap smears questionnaire.
F test (ANOVA with unbalanced design) used for all continuous variables.
*Pairwise comparisons were made only if P<0.1.
†Higher scores represent poorer psychological wellbeing.
‡χ
2 test (independent proportions) used for categorical variables.
§Median (interquartile range) number of visits or calls per questionnaire and non-parametric Kruskal-Wallis and Wilcoxon tests reported.
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The authors found that there were no differences in
outcomes between women offered a choice and those
who were not.
40 However, the details of how women
made their choice and what information they were
given are unclear. Participants were informed in a dis-
cussionwiththeirclinicianandappearedtomaketheir
choice immediately. There was no attempt to give
women standardised evidence based information on
the advantages and disadvantages of each manage-
ment. In our study, women were given an evidence
based decision aid that clearly described the advan-
tages and disadvantages of each option. Our previous
analysesofwomenintheinformedchoicearmshowed
that 78% of women were knowledgeable (scored over
50%ontheknowledgescale)and68%ofwomenmade
an informed choice.
14 This finding suggests that most
women were aware of the options and were able to
make an informed choice.
Althoughourfindingsareinformative,therearelim-
itations to the study. The area based method used to
analyse the psychological outcomes over a year of
follow-up involved both the interpolation and extra-
polation of data. We tried to minimise extrapolation
where possible and carefully excluded participants
wheresubstantialextrapolationwasrequired.Sensitiv-
ity analysis, adopting both less stringent exclusion cri-
teria, and including all data for analysis, as well as
analyses by three periods of follow-up time encom-
passing the three key events of the HPV triage, the
smeartriageandtheposttriagefollow-upshowedsimi-
lar results and interpretation, indicating that the analy-
sis method chosen is robust. The area based method is
necessary to capture the inherent time differences
between the two triage managements. Although more
complex than selecting arbitrary points in time for
comparison, it allows us to compare the entire period
ofmanagementforbotharms(includingthesixmonth
waiting time in the smear triage arm) and make max-
imum use of the longitudinal data.
As with all randomised trials, there are questions
aboutgeneralisability.Ourstudyincludedparticipants
in the national cervical screening programme from
across Australia with a range of educational
Table 4 |Psychosocial outcomes over one year
Trial arm mean scores
Overall P value
P value for pairwise comparisons*
HPV IC RS HPV v RS HPV v IC RS v IC
Quality of life
SF36: mental health
combined score
46.2 48.5 45.5 0.16 –– –
Vitality 52.8 57.1 52.5 0.18 –– –
Social function 81.6 86.7 82.4 0.17 –– –
Role emotional 80.2 83.1 75.7 0.23 –– –
Mental health 70.3 74.0 70.2 0.18 –– –
Cognitive
Perceived severity† 4.8 4.7 4.9 0.92 –– –
Perceived risk† 3.6 3.5 3.8 0.51 –– –
Intrusive thoughts†‡ 25% 13% 17% 0.19 –– –
Worry†‡ 16% 8% 15% 0.4 –– –
Satisfaction generally 14.5 14.4 13.5 0.03 0.01 – 0.03
Satisfaction with care 8.4 8.0 7.6 0.02 0.01 ––
Emotional
Anxiety (STAI)† 10.9 10.5 11.4 0.27 –– –
CSQ (distress)† 16.6 17.5 18.4 0.01 <0.01 ––
PEAPS-Q: infectivity† 2.7 2.8 2.5 0.53 –– –
PEAPS-Q:
relationships†
4.1 4.0 4.1 0.99 –– –
Relationship concern 8.7 9.1 9.0 0.15 –– –
Self esteem 31.4 31.2 31.1 0.92 –– –
Behavioural
Sexual health 9.1 8.7 8.6 0.11 –– –
Visits to GP/doctor§ 0 (0.67) 0 (0.67) 0.33 (0.75) 0.23 –– –
Calls to family planning
clinic§
0 (0) 0 (0) 0 (0.33) 0.11 –– –
RS=repeat smear, IC=informed choice, STAI=state-trait anxiety inventory, CSQ=cervical screening questionnaire, PEAPS-Q=psychosocial effects of
abnormal Pap smears questionnaire.
F test (ANOVA with unbalanced design) used for all continuous variables.
*Pairwise comparisons were made only if P<0.1.
†Higher scores represent poorer psychological wellbeing.
‡χ
2 test (independent proportions) used for categorical variables.
§Median (interquartile range) number of visits or calls per questionnaire and non-parametric Kruskal-Wallis and Wilcoxon tests reported.
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possiblyhavebeenmoreinterestedinHPVtestingand
the opportunity to choose management. However, we
note that preference for HPV testing in the informed
choicearmwas65%,whereasin a nationallyrepresen-
tative sample of Australian women we surveyed, 85%
preferredHPVtriagetesting(datanotshown).Wealso
highlightthattheofferofchoicemightbebestsuitedto
those women who want a choice in their health care,
which would make our sample appropriate.
All women in our study had conventional cytology
and therefore had to re-attend the family planning
clinic for another swab to be taken for their HPV test.
For women who undergo liquid based cytology, a
further test is not required, since the HPV triage pro-
cedure can be performed on the original cytology spe-
cimen. Our findings showed a clear overall preference
for HPV triage among women in the informed choice
group (65% v 35%). The use of liquid based cytology
andreflextestingwouldprobablyfurtherincreasepre-
ferences for HPV test among women than we have
recorded in the current study. Similarly, in the UK
HPV Sentinel Sites Implementation Project, women
testing HPV negative are returned to routine screen-
ing, rather than a 12 month smear test, as used in the
study and the ALTS protocol.
18 This change would be
further likely to favour management by HPV triage
and adds further support to this triage strategy.
CONCLUSION
Although psychosocial outcomes of management by
HPV testing for women with a borderline smear are
initially worse than with conventional management,
over 12 months, the outcomes appear to be better.
The difference between offering women a choice of
management and allocating them directly to HPV
triage appears small, with the possible advantage of
reduced intrusive thoughts and perhaps worry in the
choice arm. Overall, women were more satisfied with
HPV triage or a choice, and outcomes were worse for
womenallocatedtosmeartesting.Thefindingssuggest
that there are no lasting psychosocial disadvantages to
HPV triage, and in view of other potentialadvantages,
the findings support the move towards HPV triage in
theUKforwomenwithborderlinesmearresults.How-
ever, we note our study did not include women with
mild dyskaryosis who are currently included in NHS
Cervical Screening Programme HPV Sentinel Sites
Implementation Project. We also highlight that
women in the HPV arm were well informed about
HPV infection which might have mitigated some of
the negative psychosocial sequelae observed in pre-
vious studies. Care should be taken to ensure clear
and accessible HPV information is provided to
women alongside HPV testing.
We thank Elizabeth Davey for her advice and assistance with clinical
aspects of the IMAP trial; FPA Health (NSW), Illawarra Women’s Health
Table 5 |Knowledge scores measured at two week follow-up
Trial arm mean scores
Overall P value
P value for pairwise comparisons*
HPV test IC RS HPV v RS HPV v IC IC v RS
Knowledge score 7.3 8.1 7.2 0.01 – <0.01 0.02
Cervical smear
knowledge
4.2 4.7 3.7 <0.001 0.06 0.01 <0.001
HPV
knowledge
3.1 3.2 2.2 <0.001 <0.001 – <0.001
RS=repeat smear, IC=informed choice. F test (ANOVA with unbalanced design) used for all continuous variables.
*Pairwise comparisons were made if P<0.1.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
HPV testing for triage of women with borderline cervical abnormalities is available in the US
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